Polyplus-transfection SA, a biotechnology company that supports gene and cell therapy by supplying transfection solutions, has made available a GMP-grade transfection reagent PEIpro(R)-GMP in additional conditioning that aims to ensure additional flexibility and cost-efficiency.
 
Polyplus-transfection commercialized PEIpro-GMP at the end of 2018. This was the first transfection solution for the gene and cell therapy industry that is compliant with global cGMP viral vector manufacturing requirements. Polyplus-transfection is now expanding the PEIpro-GMP packaging options from a 1 liter single-use bag to several conditioning options from 10 milliliters up to 1 liter in both single-use bags and bottles. 
 
The use of closed-systems and single-use technologies for clinical trials and commercial manufacturing of viral vectors continues to increase. Polyplus-transfection now provides two sizes of PEIpro-GMP in bags to ensure aseptic connections to successful perform large-scale transfection in closed sterile systems. Polyplus-transfection now supplies PEIpro-GMP in bottle conditioning that will allow the adaption to different manufacturing scale-up and scale-out strategies. These increasing scale-out strategies require the performance of multiple smaller-scale transfections in multiple cell culture units at the same time. Demand for transfection reagents has increased for the smaller as well as for the larger conditioning options. 
 
“Polyplus-transfection has been developing strong supplier-manufacturer relationships over eighteen years, and certainly since the conception of the modern gene and cell therapy industries. As a result, we have unrivalled first hand visibility on the ever-changing needs of the gene and cell therapy markets,” said Claire Wartel, PhD, director of quality and compliance, Polyplus-transfection. “The focus of the market has evolved to commercialization and late-stage clinical stages. This means the therapeutic production scale and strategy needs to be adaptable to the production of each viral vector, whilst complying with cGMP manufacturing requirements. To provide this critical function in making available therapies to patients, Polyplus-technology is now able to offer a sustainable solution for viral vector platforms. This will benefit gene and cell therapy developers, the wider industry, and most importantly, the patient community reliant on the ongoing development of these therapies.”